Hint: to select multiple check boxes, press SHIFT key.
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 423 | 388 (92%) | |||||||
COVID351 | RNA_Zhang_Monocytes_severe-only_Up | 47 | scRNA-seq | Monocytes | Severe SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 14 (30%) | 44 (94%) |
COVID352 | RNA_Zhang_Monocytes_moderate-only_Up | 26 | scRNA-seq | Monocytes | Moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 15 (58%) | 22 (85%) |
COVID353 | RNA_Zhang_Monocytes_severe-and-moderate_Up | 128 | scRNA-seq | Monocytes | Severe and moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. | 87 (68%) | 122 (95%) |
COVID354 | RNA_Zhang_NK-cells_severe-only_Up | 45 | scRNA-seq | NK cells | Severe SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 40 (89%) | 41 (91%) |
COVID355 | RNA_Zhang_NK-cells_moderate-only_Up | 10 | scRNA-seq | NK cells | Moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 10 (100%) | 8 (80%) |
COVID356 | RNA_Zhang_NK-cells_severe-and-moderate_Up | 96 | scRNA-seq | NK cells | Severe and moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. | 96 (100%) | 87 (91%) |
COVID357 | RNA_Zhang_T-cells_severe-only_Up | 79 | scRNA-seq | T cells | Severe SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 41 (52%) | 69 (87%) |
COVID358 | RNA_Zhang_T-cells_moderate-only_Up | 19 | scRNA-seq | T cells | Moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 11 (58%) | 15 (79%) |
COVID359 | RNA_Zhang_T-cells_severe-and-moderate_Up | 140 | scRNA-seq | T cells | Severe and moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. | 114 (81%) | 131 (94%) |
COVID360 | RNA_Zhang_B-cells_severe-only_Up | 83 | scRNA-seq | B cells | Severe SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 21 (25%) | 78 (94%) |
COVID361 | RNA_Zhang_B-cells_moderate-only_Up | 28 | scRNA-seq | B cells | Moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. | 17 (61%) | 27 (96%) |
COVID362 | RNA_Zhang_B-cells_severe-and-moderate_Up | 75 | scRNA-seq | B cells | Severe and moderate SARS-CoV-2 | Healthy donors | Post admission | SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. | 64 (85%) | 69 (92%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 100 | 86 (86%) | |||||||
COVID079 | Interactome_Davis_HEK-293T_40h_NSP2 | 19 | Interactome | HEK-293T | NSP2 | 40h | 4 (21%) | 16 (84%) | ||
COVID080 | Interactome_Davis_HEK-293T_40h_NSP4 | 85 | Interactome | HEK-293T | NSP4 | 40h | 4 (5%) | 74 (87%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 902 | 761 (84%) | |||||||
COVID234 | Phosphoproteome_Klann_Caco-2_24h_Down | 300 | Phosphoproteome | Caco-2 | SARS-CoV-2 | Mock | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05. Features sorted by pvalue. | 65 (22%) | 255 (85%) |
COVID235 | Phosphoproteome_Klann_Caco-2_24h_Up | 300 | Phosphoproteome | Caco-2 | SARS-CoV-2 | Mock | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05. Features sorted by pvalue. | 46 (15%) | 249 (83%) |
COVID236 | Proteome_Klann_Caco-2_24h_Down | 300 | Proteome | Caco-2 | SARS-CoV-2 | Mock | 24h | Significance defined by Abs(Log2FC)>0.5 and Adj P<0.05. Features sorted by pvalue. | 32 (11%) | 258 (86%) |
COVID237 | Proteome_Klann_Caco-2_24h_Up | 75 | Proteome | Caco-2 | SARS-CoV-2 | Mock | 24h | Significance defined by Abs(Log2FC)>0.5 and Adj P<0.05. Features sorted by pvalue. | 2 (3%) | 66 (88%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1304 | 1089 (84%) | |||||||
COVID035 | RNA_Sun_Calu-3_0h_Down | 172 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 0h | 9 (5%) | 90 (52%) | |
COVID036 | RNA_Sun_Calu-3_0h_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 0h | 89 (30%) | 268 (89%) | |
COVID037 | RNA_Sun_Calu-3_12h_Down | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 12h | 129 (43%) | 269 (90%) | |
COVID038 | RNA_Sun_Calu-3_12h_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 12h | 199 (66%) | 265 (88%) | |
COVID039 | RNA_Sun_Calu-3_24h_Down | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 24h | 130 (43%) | 268 (89%) | |
COVID040 | RNA_Sun_Calu-3_24h_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 24h | 193 (64%) | 272 (91%) | |
COVID041 | RNA_Sun_Calu-3_7h_Down | 11 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 7h | 1 (9%) | 9 (82%) | |
COVID042 | RNA_Sun_Calu-3_7h_Up | 65 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 7h | 59 (91%) | 63 (97%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 460 | 384 (83%) | |||||||
COVID218 | Proteome_Bojkova_Caco-2_10h_Down | 13 | Proteome | Caco-2 | SARS-CoV-2 | Control | 10h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 6 (46%) | 7 (54%) |
COVID219 | Proteome_Bojkova_Caco-2_10h_Up | 3 | Proteome | Caco-2 | SARS-CoV-2 | Control | 10h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 2 (67%) | 2 (67%) |
COVID220 | Proteome_Bojkova_Caco-2_24h_Down | 73 | Proteome | Caco-2 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 25 (34%) | 67 (92%) |
COVID221 | Proteome_Bojkova_Caco-2_24h_Up | 42 | Proteome | Caco-2 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 9 (21%) | 30 (71%) |
COVID222 | Proteome_Bojkova_Caco-2_2h_Down | 3 | Proteome | Caco-2 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 1 (33%) | 0 (0%) |
COVID223 | Proteome_Bojkova_Caco-2_2h_Up | 2 | Proteome | Caco-2 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 2 (100%) | 1 (50%) |
COVID224 | Proteome_Bojkova_Caco-2_6h_Down | 3 | Proteome | Caco-2 | SARS-CoV-2 | Control | 6h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 1 (33%) | 2 (67%) |
COVID225 | Proteome_Bojkova_Caco-2_6h_Up | 51 | Proteome | Caco-2 | SARS-CoV-2 | Control | 6h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 13 (25%) | 40 (78%) |
COVID226 | Translatome_Bojkova_Caco-2_10h_Down | 84 | Translatome | Caco-2 | SARS-CoV-2 | Control | 10h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 33 (39%) | 70 (83%) |
COVID227 | Translatome_Bojkova_Caco-2_10h_Up | 1 | Translatome | Caco-2 | SARS-CoV-2 | Control | 10h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 0 (0%) | 1 (100%) |
COVID228 | Translatome_Bojkova_Caco-2_24h_Down | 174 | Translatome | Caco-2 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 47 (27%) | 154 (89%) |
COVID229 | Translatome_Bojkova_Caco-2_24h_Up | 44 | Translatome | Caco-2 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 4 (9%) | 37 (84%) |
COVID230 | Translatome_Bojkova_Caco-2_2h_Down | 18 | Translatome | Caco-2 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 12 (67%) | 15 (83%) |
COVID231 | Translatome_Bojkova_Caco-2_2h_Up | 13 | Translatome | Caco-2 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 2 (15%) | 10 (77%) |
COVID232 | Translatome_Bojkova_Caco-2_6h_Down | 19 | Translatome | Caco-2 | SARS-CoV-2 | Control | 6h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 3 (16%) | 14 (74%) |
COVID233 | Translatome_Bojkova_Caco-2_6h_Up | 3 | Translatome | Caco-2 | SARS-CoV-2 | Control | 6h | Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. | 3 (100%) | 3 (100%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1063 | 884 (83%) | |||||||
COVID244 | RNA_Wilk_CD14+Monocytes_patient-C1A-mild_Up | 82 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 82 (100%) | 82 (100%) |
COVID245 | RNA_Wilk_CD14+Monocytes_patient-C1A-mild_Down | 58 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 56 (97%) | 53 (91%) |
COVID246 | RNA_Wilk_CD14+Monocytes_patient-C1B-severe_Up | 77 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 75 (97%) | 75 (97%) |
COVID247 | RNA_Wilk_CD14+Monocytes_patient-C1B-severe_Down | 62 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 62 (100%) | 59 (95%) |
COVID248 | RNA_Wilk_CD14+Monocytes_patient-C2_Up | 63 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 58 (92%) | 61 (97%) |
COVID249 | RNA_Wilk_CD14+Monocytes_patient-C2_Down | 65 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 62 (95%) | 57 (88%) |
COVID250 | RNA_Wilk_CD14+Monocytes_patient-C3_Up | 51 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 49 (96%) | 48 (94%) |
COVID251 | RNA_Wilk_CD14+Monocytes_patient-C3_Down | 61 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 61 (100%) | 57 (93%) |
COVID252 | RNA_Wilk_CD14+Monocytes_patient-C4_Up | 80 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 80 (100%) | 78 (98%) |
COVID253 | RNA_Wilk_CD14+Monocytes_patient-C4_Down | 102 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 97 (95%) | 91 (89%) |
COVID254 | RNA_Wilk_CD14+Monocytes_patient-C5_Up | 106 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 103 (97%) | 101 (95%) |
COVID255 | RNA_Wilk_CD14+Monocytes_patient-C5_Down | 146 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 117 (80%) | 130 (89%) |
COVID256 | RNA_Wilk_CD14+Monocytes_patient-C6_Up | 157 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 140 (89%) | 145 (92%) |
COVID257 | RNA_Wilk_CD14+Monocytes_patient-C6_Down | 89 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 83 (93%) | 82 (92%) |
COVID258 | RNA_Wilk_CD14+Monocytes_patient-C7_Up | 32 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 29 (91%) | 29 (91%) |
COVID259 | RNA_Wilk_CD14+Monocytes_patient-C7_Down | 34 | scRNA-seq | CD14+ Monocytes | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 34 (100%) | 31 (91%) |
COVID260 | RNA_Wilk_CD16+Monocytes_patient-C1A-mild_Up | 75 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 67 (89%) | 71 (95%) |
COVID261 | RNA_Wilk_CD16+Monocytes_patient-C1A-mild_Down | 17 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 17 (100%) | 16 (94%) |
COVID262 | RNA_Wilk_CD16+Monocytes_patient-C1B-severe_Up | 49 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 43 (88%) | 48 (98%) |
COVID263 | RNA_Wilk_CD16+Monocytes_patient-C1B-severe_Down | 12 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 12 (100%) | 12 (100%) |
COVID264 | RNA_Wilk_CD16+Monocytes_patient-C3_Up | 39 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 35 (90%) | 36 (92%) |
COVID265 | RNA_Wilk_CD16+Monocytes_patient-C3_Down | 1 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 1 (100%) | 1 (100%) |
COVID266 | RNA_Wilk_CD16+Monocytes_patient-C4_Up | 77 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 71 (92%) | 77 (100%) |
COVID267 | RNA_Wilk_CD16+Monocytes_patient-C4_Down | 16 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 16 (100%) | 15 (94%) |
COVID268 | RNA_Wilk_CD16+Monocytes_patient-C5_Up | 101 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 73 (72%) | 91 (90%) |
COVID269 | RNA_Wilk_CD16+Monocytes_patient-C5_Down | 6 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 6 (100%) | 6 (100%) |
COVID270 | RNA_Wilk_CD16+Monocytes_patient-C6_Up | 31 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 27 (87%) | 28 (90%) |
COVID271 | RNA_Wilk_CD16+Monocytes_patient-C7_Up | 26 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 26 (100%) | 26 (100%) |
COVID272 | RNA_Wilk_CD16+Monocytes_patient-C7_Down | 27 | scRNA-seq | CD16+ Monocytes | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 20 (74%) | 24 (89%) |
COVID273 | RNA_Wilk_Dendritic-cells_patient-C1A-mild_Up | 40 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 40 (100%) | 40 (100%) |
COVID274 | RNA_Wilk_Dendritic-cells_patient-C1A-mild_Down | 2 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 2 (100%) | 2 (100%) |
COVID275 | RNA_Wilk_Dendritic-cells_patient-C1B-severe_Up | 15 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 14 (93%) | 15 (100%) |
COVID276 | RNA_Wilk_Dendritic-cells_patient-C1B-severe_Down | 2 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 2 (100%) | 2 (100%) |
COVID277 | RNA_Wilk_Dendritic-cells_patient-C2_Up | 74 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 3 (4%) | 31 (42%) |
COVID278 | RNA_Wilk_Dendritic-cells_patient-C3_Up | 12 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 12 (100%) | 9 (75%) |
COVID279 | RNA_Wilk_Dendritic-cells_patient-C3_Down | 1 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 1 (100%) | 1 (100%) |
COVID280 | RNA_Wilk_Dendritic-cells_patient-C4_Up | 25 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 25 (100%) | 25 (100%) |
COVID281 | RNA_Wilk_Dendritic-cells_patient-C4_Down | 18 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 18 (100%) | 15 (83%) |
COVID282 | RNA_Wilk_Dendritic-cells_patient-C5_Up | 73 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 67 (92%) | 72 (99%) |
COVID283 | RNA_Wilk_Dendritic-cells_patient-C5_Down | 23 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 22 (96%) | 19 (83%) |
COVID284 | RNA_Wilk_Dendritic-cells_patient-C6_Up | 18 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 13 (72%) | 14 (78%) |
COVID285 | RNA_Wilk_Dendritic-cells_patient-C7_Up | 29 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 27 (93%) | 27 (93%) |
COVID286 | RNA_Wilk_Dendritic-cells_patient-C7_Down | 27 | scRNA-seq | Dendritic cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 22 (81%) | 25 (93%) |
COVID287 | RNA_Wilk_NK-cells_patient-C1A-mild_Up | 34 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 34 (100%) | 32 (94%) |
COVID288 | RNA_Wilk_NK-cells_patient-C1A-mild_Down | 16 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 16 (100%) | 15 (94%) |
COVID289 | RNA_Wilk_NK-cells_patient-C1B-severe_Up | 12 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 8 (67%) | 8 (67%) |
COVID290 | RNA_Wilk_NK-cells_patient-C1B-severe_Down | 14 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 14 (100%) | 12 (86%) |
COVID291 | RNA_Wilk_NK-cells_patient-C2_Up | 5 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 4 (80%) | 4 (80%) |
COVID292 | RNA_Wilk_NK-cells_patient-C2_Down | 7 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 5 (71%) | 7 (100%) |
COVID293 | RNA_Wilk_NK-cells_patient-C3_Up | 25 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 23 (92%) | 24 (96%) |
COVID294 | RNA_Wilk_NK-cells_patient-C3_Down | 8 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 8 (100%) | 7 (88%) |
COVID295 | RNA_Wilk_NK-cells_patient-C4_Up | 24 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 23 (96%) | 23 (96%) |
COVID296 | RNA_Wilk_NK-cells_patient-C4_Down | 22 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 22 (100%) | 21 (95%) |
COVID297 | RNA_Wilk_NK-cells_patient-C5_Up | 52 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 43 (83%) | 48 (92%) |
COVID298 | RNA_Wilk_NK-cells_patient-C5_Down | 29 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 26 (90%) | 27 (93%) |
COVID299 | RNA_Wilk_NK-cells_patient-C6_Up | 31 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 29 (94%) | 31 (100%) |
COVID300 | RNA_Wilk_NK-cells_patient-C6_Down | 4 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 4 (100%) | 4 (100%) |
COVID301 | RNA_Wilk_NK-cells_patient-C7_Up | 5 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 5 (100%) | 5 (100%) |
COVID302 | RNA_Wilk_NK-cells_patient-C7_Down | 30 | scRNA-seq | NK cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 20 (67%) | 27 (90%) |
COVID303 | RNA_Wilk_CD8+T-cells_patient-C1A-mild_Up | 19 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 19 (100%) | 19 (100%) |
COVID304 | RNA_Wilk_CD8+T-cells_patient-C1A-mild_Down | 23 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 20 (87%) | 18 (78%) |
COVID305 | RNA_Wilk_CD8+T-cells_patient-C1B-severe_Up | 10 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 10 (100%) | 9 (90%) |
COVID306 | RNA_Wilk_CD8+T-cells_patient-C1B-severe_Down | 9 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 9 (100%) | 8 (89%) |
COVID307 | RNA_Wilk_CD8+T-cells_patient-C2_Up | 11 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 11 (100%) | 10 (91%) |
COVID308 | RNA_Wilk_CD8+T-cells_patient-C2_Down | 10 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 9 (90%) | 8 (80%) |
COVID309 | RNA_Wilk_CD8+T-cells_patient-C3_Up | 34 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 32 (94%) | 32 (94%) |
COVID310 | RNA_Wilk_CD8+T-cells_patient-C3_Down | 5 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 5 (100%) | 5 (100%) |
COVID311 | RNA_Wilk_CD8+T-cells_patient-C4_Up | 22 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 22 (100%) | 22 (100%) |
COVID312 | RNA_Wilk_CD8+T-cells_patient-C4_Down | 31 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 31 (100%) | 30 (97%) |
COVID313 | RNA_Wilk_CD8+T-cells_patient-C5_Up | 43 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 41 (95%) | 42 (98%) |
COVID314 | RNA_Wilk_CD8+T-cells_patient-C5_Down | 45 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 39 (87%) | 39 (87%) |
COVID315 | RNA_Wilk_CD8+T-cells_patient-C6_Up | 43 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 39 (91%) | 42 (98%) |
COVID316 | RNA_Wilk_CD8+T-cells_patient-C6_Down | 11 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 11 (100%) | 11 (100%) |
COVID317 | RNA_Wilk_CD8+T-cells_patient-C7_Up | 4 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 4 (100%) | 2 (50%) |
COVID318 | RNA_Wilk_CD8+T-cells_patient-C7_Down | 12 | scRNA-seq | CD8+ T cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 10 (83%) | 10 (83%) |
COVID319 | RNA_Wilk_CD4+T-cells_patient-C1A-mild_Up | 40 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 40 (100%) | 40 (100%) |
COVID320 | RNA_Wilk_CD4+T-cells_patient-C1A-mild_Down | 34 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 33 (97%) | 28 (82%) |
COVID321 | RNA_Wilk_CD4+T-cells_patient-C1B-severe_Up | 13 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 13 (100%) | 13 (100%) |
COVID322 | RNA_Wilk_CD4+T-cells_patient-C1B-severe_Down | 7 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 7 (100%) | 7 (100%) |
COVID323 | RNA_Wilk_CD4+T-cells_patient-C2_Up | 22 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 19 (86%) | 21 (95%) |
COVID324 | RNA_Wilk_CD4+T-cells_patient-C2_Down | 10 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 10 (100%) | 9 (90%) |
COVID325 | RNA_Wilk_CD4+T-cells_patient-C3_Up | 15 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 14 (93%) | 15 (100%) |
COVID326 | RNA_Wilk_CD4+T-cells_patient-C3_Down | 6 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 6 (100%) | 6 (100%) |
COVID327 | RNA_Wilk_CD4+T-cells_patient-C4_Up | 24 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 24 (100%) | 24 (100%) |
COVID328 | RNA_Wilk_CD4+T-cells_patient-C4_Down | 31 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 30 (97%) | 27 (87%) |
COVID329 | RNA_Wilk_CD4+T-cells_patient-C5_Up | 39 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 39 (100%) | 39 (100%) |
COVID330 | RNA_Wilk_CD4+T-cells_patient-C5_Down | 32 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 31 (97%) | 29 (91%) |
COVID331 | RNA_Wilk_CD4+T-cells_patient-C6_Up | 39 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 33 (85%) | 36 (92%) |
COVID332 | RNA_Wilk_CD4+T-cells_patient-C6_Down | 12 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 11 (92%) | 11 (92%) |
COVID333 | RNA_Wilk_CD4+T-cells_patient-C7_Up | 8 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 7 (88%) | 7 (88%) |
COVID334 | RNA_Wilk_CD4+T-cells_patient-C7_Down | 11 | scRNA-seq | CD4+ T cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 10 (91%) | 10 (91%) |
COVID335 | RNA_Wilk_B-cells_patient-C1A-mild_Up | 64 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 64 (100%) | 63 (98%) |
COVID336 | RNA_Wilk_B-cells_patient-C1A-mild_Down | 62 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 62 (100%) | 52 (84%) |
COVID337 | RNA_Wilk_B-cells_patient-C1B-severe_Up | 107 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 99 (93%) | 96 (90%) |
COVID338 | RNA_Wilk_B-cells_patient-C1B-severe_Down | 78 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 11d post onset | SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 78 (100%) | 69 (88%) |
COVID339 | RNA_Wilk_B-cells_patient-C2_Up | 35 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 34 (97%) | 35 (100%) |
COVID340 | RNA_Wilk_B-cells_patient-C2_Down | 21 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 16d post onset | SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 21 (100%) | 18 (86%) |
COVID341 | RNA_Wilk_B-cells_patient-C3_Up | 84 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 82 (98%) | 80 (95%) |
COVID342 | RNA_Wilk_B-cells_patient-C3_Down | 30 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 30 (100%) | 28 (93%) |
COVID343 | RNA_Wilk_B-cells_patient-C4_Up | 126 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 109 (87%) | 118 (94%) |
COVID344 | RNA_Wilk_B-cells_patient-C4_Down | 172 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 9d post onset | SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 169 (98%) | 146 (85%) |
COVID345 | RNA_Wilk_B-cells_patient-C5_Up | 119 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 110 (92%) | 112 (94%) |
COVID346 | RNA_Wilk_B-cells_patient-C5_Down | 184 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 15d post onset | SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 167 (91%) | 157 (85%) |
COVID347 | RNA_Wilk_B-cells_patient-C6_Up | 114 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 54 (47%) | 102 (89%) |
COVID348 | RNA_Wilk_B-cells_patient-C6_Down | 34 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 2d post onset | SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 34 (100%) | 32 (94%) |
COVID349 | RNA_Wilk_B-cells_patient-C7_Up | 5 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 5 (100%) | 5 (100%) |
COVID350 | RNA_Wilk_B-cells_patient-C7_Down | 42 | scRNA-seq | B cells | SARS-CoV-2 | Healthy | 12d post onset | SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. | 40 (95%) | 39 (93%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 416 | 345 (83%) | |||||||
COVID238 | RNA_Lieberman_Nasopharynx_Infected_vs_Neg_Down | 43 | RNA-seq | Nasopharynx | SARS-CoV-2 | Negative | Significance defined by Abs(Log2FC)>1 and Adj P<0.1. Features sorted by pvalue. | 9 (21%) | 41 (95%) | |
COVID239 | RNA_Lieberman_Nasopharynx_Infected_vs_Neg_Up | 41 | RNA-seq | Nasopharynx | SARS-CoV-2 | Negative | Significance defined by Abs(Log2FC)>1 and Adj P<0.1. Features sorted by pvalue. | 22 (54%) | 39 (95%) | |
COVID240 | RNA_Lieberman_Nasopharynx_High_vs_Low_Down | 190 | RNA-seq | Nasopharynx | SARS-CoV-2 High Viral Load | SARS-CoV-2 Low Viral Load | Significance defined by Adj P<0.1. Features sorted by pvalue. | 10 (5%) | 149 (78%) | |
COVID241 | RNA_Lieberman_Nasopharynx_High_vs_Low_Up | 173 | RNA-seq | Nasopharynx | SARS-CoV-2 High Viral Load | SARS-CoV-2 Low Viral Load | Significance defined by Adj P<0.1. Features sorted by pvalue. | 21 (12%) | 146 (84%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 381 | 314 (82%) | |||||||
COVID242 | RNA_Riva_Vero-E6_24h_Down | 81 | RNA-seq | Vero-E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.01. Features sorted by pvalue. | 0 (0%) | 58 (72%) |
COVID243 | RNA_Riva_Vero-E6_24h_Up | 300 | RNA-seq | Vero-E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.01. Features sorted by pvalue. | 0 (0%) | 256 (85%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1276 | 1020 (80%) | |||||||
COVID055 | Phosphoproteome_Bouhaddou_Vero_E6_0h_Down | 283 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 0h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 222 (78%) | 236 (83%) |
COVID056 | Phosphoproteome_Bouhaddou_Vero_E6_0h_Up | 184 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 0h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 143 (78%) | 151 (82%) |
COVID057 | Phosphoproteome_Bouhaddou_Vero_E6_12h_Down | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 12h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 290 (97%) | 247 (82%) |
COVID058 | Phosphoproteome_Bouhaddou_Vero_E6_12h_Up | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 12h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 276 (92%) | 245 (82%) |
COVID059 | Phosphoproteome_Bouhaddou_Vero_E6_24h_Down | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 254 (85%) | 244 (81%) |
COVID060 | Phosphoproteome_Bouhaddou_Vero_E6_24h_Up | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 228 (76%) | 248 (83%) |
COVID061 | Phosphoproteome_Bouhaddou_Vero_E6_2h_Down | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 248 (83%) | 244 (81%) |
COVID062 | Phosphoproteome_Bouhaddou_Vero_E6_2h_Up | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 272 (91%) | 244 (81%) |
COVID063 | Phosphoproteome_Bouhaddou_Vero_E6_4h_Down | 201 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 4h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 191 (95%) | 168 (84%) |
COVID064 | Phosphoproteome_Bouhaddou_Vero_E6_4h_Up | 263 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 4h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 246 (94%) | 211 (80%) |
COVID065 | Phosphoproteome_Bouhaddou_Vero_E6_8h_Down | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 8h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 276 (92%) | 250 (83%) |
COVID066 | Phosphoproteome_Bouhaddou_Vero_E6_8h_Up | 300 | Phosphoproteome | Vero_E6 | SARS-CoV-2 | Control | 8h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 280 (93%) | 244 (81%) |
COVID067 | Proteome_Bouhaddou_Vero_E6_0h_Down | 10 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 0h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 4 (40%) | 9 (90%) |
COVID068 | Proteome_Bouhaddou_Vero_E6_0h_Up | 1 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 0h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 0 (0%) | 1 (100%) |
COVID069 | Proteome_Bouhaddou_Vero_E6_12h_Down | 53 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 12h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 50 (94%) | 49 (92%) |
COVID070 | Proteome_Bouhaddou_Vero_E6_12h_Up | 6 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 12h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 6 (100%) | 3 (50%) |
COVID071 | Proteome_Bouhaddou_Vero_E6_24h_Down | 97 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 61 (63%) | 86 (89%) |
COVID072 | Proteome_Bouhaddou_Vero_E6_24h_Up | 16 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 24h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 8 (50%) | 10 (62%) |
COVID073 | Proteome_Bouhaddou_Vero_E6_2h_Down | 43 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 40 (93%) | 39 (91%) |
COVID074 | Proteome_Bouhaddou_Vero_E6_2h_Up | 6 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 2h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 4 (67%) | 3 (50%) |
COVID075 | Proteome_Bouhaddou_Vero_E6_4h_Down | 33 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 4h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 33 (100%) | 29 (88%) |
COVID076 | Proteome_Bouhaddou_Vero_E6_4h_Up | 3 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 4h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 3 (100%) | 0 (0%) |
COVID077 | Proteome_Bouhaddou_Vero_E6_8h_Down | 45 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 8h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 42 (93%) | 41 (91%) |
COVID078 | Proteome_Bouhaddou_Vero_E6_8h_Up | 6 | Proteome | Vero_E6 | SARS-CoV-2 | Control | 8h | Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. | 5 (83%) | 3 (50%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1801 | 1408 (78%) | |||||||
COVID007 | RNA_Blanco-Melo_A549_Down | 300 | RNA-seq | A549 | SARS-CoV-2 | uninfected | 9h | 138 (46%) | 237 (79%) | |
COVID008 | RNA_Blanco-Melo_A549_Up | 300 | RNA-seq | A549 | SARS-CoV-2 | uninfected | 9h | 108 (36%) | 244 (81%) | |
COVID009 | RNA_Blanco-Melo_A549-ACE2_Down | 207 | RNA-seq | A549 w/ exogenous ACE2 | SARS-CoV-2 | uninfected | 9h | 54 (26%) | 162 (78%) | |
COVID010 | RNA_Blanco-Melo_A549-ACE2_Up | 300 | RNA-seq | A549 w/ exogenous ACE2 | SARS-CoV-2 | uninfected | 9h | 88 (29%) | 234 (78%) | |
COVID011 | RNA_Blanco-Melo_A549-ACE2-ruxolitinib_Down | 234 | RNA-seq | A549 w/ exogenous ACE2 | SARS-CoV-2 and ruxolitinib | SARS-CoV-2 | 9h | 142 (61%) | 211 (90%) | |
COVID012 | RNA_Blanco-Melo_A549-ACE2-ruxolitinib_Up | 8 | RNA-seq | A549 w/ exogenous ACE2 | SARS-CoV-2 and ruxolitinib | SARS-CoV-2 | 9h | 5 (62%) | 6 (75%) | |
COVID013 | RNA_Blanco-Melo_A549-low-MOI_Down | 1 | RNA-seq | A549 | SARS-CoV-2 (low MOI) | uninfected | 9h | 1 (100%) | 1 (100%) | |
COVID014 | RNA_Blanco-Melo_A549-low-MOI_Up | 35 | RNA-seq | A549 | SARS-CoV-2 (low MOI) | uninfected | 9h | 35 (100%) | 35 (100%) | |
COVID015 | RNA_Blanco-Melo_Calu-3_Down | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 9h | 130 (43%) | 240 (80%) | |
COVID016 | RNA_Blanco-Melo_Calu-3_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 9h | 218 (73%) | 287 (96%) | |
COVID017 | RNA_Blanco-Melo_Lung_Down | 262 | RNA-seq | Lung | SARS-CoV-2 | uninfected | post-mortem | 73 (28%) | 186 (71%) | |
COVID018 | RNA_Blanco-Melo_Lung_Up | 84 | RNA-seq | Lung | SARS-CoV-2 | uninfected | post-mortem | 23 (27%) | 63 (75%) | |
COVID019 | RNA_Blanco-Melo_NHBE_Down | 11 | RNA-seq | NHBE | SARS-CoV-2 | uninfected | 24h | 1 (9%) | 8 (73%) | |
COVID020 | RNA_Blanco-Melo_NHBE_Up | 86 | RNA-seq | NHBE | SARS-CoV-2 | uninfected | 24h | 63 (73%) | 79 (92%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 137 | 107 (78%) | |||||||
COVID210 | Proteome_Shen_Serum-severe-vs-nonsevere_Up | 26 | Proteome | Serum | SARS-CoV-2 (severe) | SARS-CoV-2 (mild) | Significance defined by Supp Table. Features sorted by pvalue. | 26 (100%) | 20 (77%) | |
COVID211 | Proteome_Shen_Serum-severe-vs-nonsevere_Down | 16 | Proteome | Serum | SARS-CoV-2 (severe) | SARS-CoV-2 (mild) | Significance defined by Supp Table. Features sorted by pvalue. | 15 (94%) | 13 (81%) | |
COVID212 | Proteome_Shen_Serum-severe-vs-healthy_Up | 63 | Proteome | Serum | SARS-CoV-2 (severe) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 35 (56%) | 52 (83%) | |
COVID213 | Proteome_Shen_Serum-severe-vs-healthy_Down | 59 | Proteome | Serum | SARS-CoV-2 (severe) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 37 (63%) | 42 (71%) | |
COVID214 | Proteome_Shen_Serum-nonCovid-vs-healthy_Up | 15 | Proteome | Serum | Non-SARS-CoV-2 patient | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 11 (73%) | 14 (93%) | |
COVID215 | Proteome_Shen_Serum-nonCovid-vs-healthy_Down | 13 | Proteome | Serum | Non-SARS-CoV-2 patient | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 13 (100%) | 9 (69%) | |
COVID216 | Proteome_Shen_Serum-nonsevere-vs-healthy_Up | 21 | Proteome | Serum | SARS-CoV-2 (mild) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 15 (71%) | 16 (76%) | |
COVID217 | Proteome_Shen_Serum-nonsevere-vs-healthy_Down | 23 | Proteome | Serum | SARS-CoV-2 (mild) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 20 (87%) | 18 (78%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1048 | 818 (78%) | |||||||
COVID043 | RNA_Wyler_Caco-2_12h_Down | 126 | RNA-seq | Caco-2 | SARS-CoV-2 | uninfected | 12h | 38 (30%) | 85 (67%) | |
COVID044 | RNA_Wyler_Caco-2_12h_Up | 29 | RNA-seq | Caco-2 | SARS-CoV-2 | uninfected | 12h | 17 (59%) | 22 (76%) | |
COVID045 | RNA_Wyler_Caco-2_24h_Down | 33 | RNA-seq | Caco-2 | SARS-CoV-2 | uninfected | 24h | 21 (64%) | 24 (73%) | |
COVID046 | RNA_Wyler_Caco-2_24h_Up | 97 | RNA-seq | Caco-2 | SARS-CoV-2 | uninfected | 24h | 39 (40%) | 77 (79%) | |
COVID047 | RNA_Wyler_Calu-3_12h_Down | 195 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 12h | 41 (21%) | 122 (63%) | |
COVID048 | RNA_Wyler_Calu-3_12h_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 12h | 214 (71%) | 286 (95%) | |
COVID049 | RNA_Wyler_Calu-3_24h_Down | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 24h | 49 (16%) | 222 (74%) | |
COVID050 | RNA_Wyler_Calu-3_24h_Up | 300 | RNA-seq | Calu-3 | SARS-CoV-2 | uninfected | 24h | 218 (73%) | 285 (95%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 494 | 385 (78%) | |||||||
COVID204 | Proteome_Li_Urine-severe-vs-healthy_Up | 84 | Proteome | Urine | SARS-CoV-2 (severe) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 53 (63%) | 70 (83%) | |
COVID205 | Proteome_Li_Urine-severe-vs-healthy_Down | 171 | Proteome | Urine | SARS-CoV-2 (severe) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 107 (63%) | 125 (73%) | |
COVID206 | Proteome_Li_Urine-mild-vs-healthy_Up | 86 | Proteome | Urine | SARS-CoV-2 (mild) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 54 (63%) | 71 (83%) | |
COVID207 | Proteome_Li_Urine-mild-vs-healthy_Down | 99 | Proteome | Urine | SARS-CoV-2 (mild) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 86 (87%) | 70 (71%) | |
COVID208 | Proteome_Li_Urine-recovery-vs-healthy_Up | 153 | Proteome | Urine | SARS-CoV-2 (in recovery) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 45 (29%) | 123 (80%) | |
COVID209 | Proteome_Li_Urine-recovery-vs-healthy_Down | 127 | Proteome | Urine | SARS-CoV-2 (in recovery) | Healthy | Significance defined by Supp Table. Features sorted by pvalue. | 63 (50%) | 96 (76%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 485 | 375 (77%) | |||||||
COVID025 | RNA_Lamers_intestinal-organoid_differentiated_Down | 46 | RNA-seq | intestinal organoid (differentiation medium) | SARS-CoV-2 | uninfected | 60h | 22 (48%) | 34 (74%) | |
COVID026 | RNA_Lamers_intestinal-organoid_differentiated_Up | 36 | RNA-seq | intestinal organoid (differentiation medium) | SARS-CoV-2 | uninfected | 60h | 14 (39%) | 27 (75%) | |
COVID027 | RNA_Lamers_intestinal-organoid_expansion_Down | 267 | RNA-seq | intestinal-organoid (expansion medium) | SARS-CoV-2 | uninfected | 60h | 20 (7%) | 203 (76%) | |
COVID028 | RNA_Lamers_intestinal-organoid_expansion_Up | 172 | RNA-seq | intestinal-organoid (expansion medium) | SARS-CoV-2 | uninfected | 60h | 16 (9%) | 141 (82%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 333 | 247 (74%) | |||||||
COVID081 | Interactome_Gordon_HEK-293T_38h_E | 6 | Interactome | HEK-293T | E | 38h | 0 (0%) | 5 (83%) | ||
COVID082 | Interactome_Gordon_HEK-293T_38h_M | 30 | Interactome | HEK-293T | M | 38h | 0 (0%) | 22 (73%) | ||
COVID083 | Interactome_Gordon_HEK-293T_38h_N | 15 | Interactome | HEK-293T | N | 38h | 0 (0%) | 13 (87%) | ||
COVID084 | Interactome_Gordon_HEK-293T_38h_NSP1 | 6 | Interactome | HEK-293T | NSP1 | 38h | 0 (0%) | 6 (100%) | ||
COVID085 | Interactome_Gordon_HEK-293T_38h_NSP10 | 5 | Interactome | HEK-293T | NSP10 | 38h | 0 (0%) | 4 (80%) | ||
COVID086 | Interactome_Gordon_HEK-293T_38h_NSP11 | 1 | Interactome | HEK-293T | NSP11 | 38h | 0 (0%) | 0 (0%) | ||
COVID087 | Interactome_Gordon_HEK-293T_38h_NSP12 | 20 | Interactome | HEK-293T | NSP12 | 38h | 0 (0%) | 15 (75%) | ||
COVID088 | Interactome_Gordon_HEK-293T_38h_NSP13 | 41 | Interactome | HEK-293T | NSP13 | 38h | 0 (0%) | 24 (59%) | ||
COVID089 | Interactome_Gordon_HEK-293T_38h_NSP14 | 3 | Interactome | HEK-293T | NSP14 | 38h | 0 (0%) | 3 (100%) | ||
COVID090 | Interactome_Gordon_HEK-293T_38h_NSP15 | 3 | Interactome | HEK-293T | NSP15 | 38h | 0 (0%) | 2 (67%) | ||
COVID091 | Interactome_Gordon_HEK-293T_38h_NSP2 | 7 | Interactome | HEK-293T | NSP2 | 38h | 0 (0%) | 5 (71%) | ||
COVID092 | Interactome_Gordon_HEK-293T_38h_NSP4 | 8 | Interactome | HEK-293T | NSP4 | 38h | 0 (0%) | 6 (75%) | ||
COVID093 | Interactome_Gordon_HEK-293T_38h_NSP5 | 1 | Interactome | HEK-293T | NSP5 | 38h | 0 (0%) | 1 (100%) | ||
COVID094 | Interactome_Gordon_HEK-293T_38h_NSP5_C145A | 2 | Interactome | HEK-293T | NSP5_C145A | 38h | 0 (0%) | 1 (50%) | ||
COVID095 | Interactome_Gordon_HEK-293T_38h_NSP6 | 4 | Interactome | HEK-293T | NSP6 | 38h | 0 (0%) | 3 (75%) | ||
COVID096 | Interactome_Gordon_HEK-293T_38h_NSP7 | 32 | Interactome | HEK-293T | NSP7 | 38h | 0 (0%) | 24 (75%) | ||
COVID097 | Interactome_Gordon_HEK-293T_38h_NSP8 | 24 | Interactome | HEK-293T | NSP8 | 38h | 0 (0%) | 18 (75%) | ||
COVID098 | Interactome_Gordon_HEK-293T_38h_NSP9 | 16 | Interactome | HEK-293T | NSP9 | 38h | 0 (0%) | 13 (81%) | ||
COVID099 | Interactome_Gordon_HEK-293T_38h_ORF10 | 9 | Interactome | HEK-293T | ORF10 | 38h | 0 (0%) | 9 (100%) | ||
COVID100 | Interactome_Gordon_HEK-293T_38h_ORF3A | 8 | Interactome | HEK-293T | ORF3A | 38h | 0 (0%) | 7 (88%) | ||
COVID101 | Interactome_Gordon_HEK-293T_38h_ORF3B | 1 | Interactome | HEK-293T | ORF3B | 38h | 0 (0%) | 1 (100%) | ||
COVID102 | Interactome_Gordon_HEK-293T_38h_ORF6 | 3 | Interactome | HEK-293T | ORF6 | 38h | 0 (0%) | 2 (67%) | ||
COVID103 | Interactome_Gordon_HEK-293T_38h_ORF7A | 2 | Interactome | HEK-293T | ORF7A | 38h | 0 (0%) | 2 (100%) | ||
COVID104 | Interactome_Gordon_HEK-293T_38h_ORF8 | 47 | Interactome | HEK-293T | ORF8 | 38h | 0 (0%) | 32 (68%) | ||
COVID105 | Interactome_Gordon_HEK-293T_38h_ORF9B | 11 | Interactome | HEK-293T | ORF9B | 38h | 0 (0%) | 10 (91%) | ||
COVID106 | Interactome_Gordon_HEK-293T_38h_ORF9C | 26 | Interactome | HEK-293T | ORF9C | 38h | 0 (0%) | 17 (65%) | ||
COVID107 | Interactome_Gordon_HEK-293T_38h_S | 2 | Interactome | HEK-293T | S | 38h | 0 (0%) | 2 (100%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1151 | 774 (67%) | |||||||
COVID051 | RNA_Xiong_BALF_Down | 300 | RNA-seq | BALF | SARS-CoV-2 | uninfected | 3 (1%) | 245 (82%) | ||
COVID052 | RNA_Xiong_BALF_Up | 300 | RNA-seq | BALF | SARS-CoV-2 | uninfected | 9 (3%) | 214 (71%) | ||
COVID053 | RNA_Xiong_PBMC_Down | 263 | RNA-seq | PBMC | SARS-CoV-2 | uninfected | 7 (3%) | 117 (44%) | ||
COVID054 | RNA_Xiong_PBMC_Up | 300 | RNA-seq | PBMC | SARS-CoV-2 | uninfected | 5 (2%) | 206 (69%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 351 | 235 (67%) | |||||||
COVID202 | RNA_Vanderheiden_pHAE_48h_Down | 193 | RNA-seq | pHAE | SARS-CoV-2 | Mock | 48h | Significance defined by Log2FC >= 1.0 and adjusted p-value < 0.01. Features sorted by pvalue. | 0 (0%) | 125 (65%) |
COVID203 | RNA_Vanderheiden_pHAE_48h_Up | 158 | RNA-seq | pHAE | SARS-CoV-2 | Mock | 48h | Significance defined by Log2FC >= 1.0 and adjusted p-value < 0.01. Features sorted by pvalue. | 0 (0%) | 110 (70%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 631 | 410 (65%) | |||||||
COVID001 | RNA_Appelberg_Huh-7_24h_Down | 6 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 24h | 2 (33%) | 4 (67%) | |
COVID002 | RNA_Appelberg_Huh-7_24h_Up | 8 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 24h | 2 (25%) | 7 (88%) | |
COVID003 | RNA_Appelberg_Huh-7_48h_Down | 23 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 48h | 17 (74%) | 17 (74%) | |
COVID004 | RNA_Appelberg_Huh-7_48h_Up | 97 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 48h | 83 (86%) | 41 (42%) | |
COVID005 | RNA_Appelberg_Huh-7_72h_Down | 300 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 72h | 16 (5%) | 231 (77%) | |
COVID006 | RNA_Appelberg_Huh-7_72h_Up | 300 | RNA-seq | Huh-7 | SARS-CoV-2 | uninfected | 72h | 84 (28%) | 162 (54%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 792 | 496 (63%) | |||||||
COVID021 | RNA_Keller_B-cells-CD21pos_infection_Down | 24 | RNA-seq | B cells | SARS-CoV-2 (CD21+) | uninfected (CD21+) | 5 (21%) | 17 (71%) | ||
COVID022 | RNA_Keller_B-cells-CD21pos_infection_Up | 275 | RNA-seq | B cells | SARS-CoV-2 (CD21+) | uninfected (CD21+) | 86 (31%) | 175 (64%) | ||
COVID023 | RNA_Keller_B-cells-Infected_CD21pos_Down | 284 | RNA-seq | B cells | SARS-CoV-2 (CD21+) | SARS-CoV-2 (CD21 low) | 82 (29%) | 182 (64%) | ||
COVID024 | RNA_Keller_B-cells-Infected_CD21pos_Up | 300 | RNA-seq | B cells | SARS-CoV-2 (CD21+) | SARS-CoV-2 (CD21 low) | 9 (3%) | 175 (58%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 4695 | 2816 (60%) | |||||||
COVID108 | Interactome_Stukalov_A549_72h_E | 11 | Interactome | A549 | E | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 7 (64%) | 6 (55%) | |
COVID109 | Interactome_Stukalov_A549_72h_M | 139 | Interactome | A549 | M | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 68 (49%) | 71 (51%) | |
COVID110 | Interactome_Stukalov_A549_72h_N | 9 | Interactome | A549 | N | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 6 (67%) | 6 (67%) | |
COVID111 | Interactome_Stukalov_A549_72h_NSP1 | 3 | Interactome | A549 | NSP1 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 3 (100%) | 2 (67%) | |
COVID112 | Interactome_Stukalov_A549_72h_NSP12 | 1 | Interactome | A549 | NSP12 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 1 (100%) | 1 (100%) | |
COVID113 | Interactome_Stukalov_A549_72h_NSP13 | 1 | Interactome | A549 | NSP13 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 0 (0%) | 0 (0%) | |
COVID114 | Interactome_Stukalov_A549_72h_NSP14 | 2 | Interactome | A549 | NSP14 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 0 (0%) | 1 (50%) | |
COVID115 | Interactome_Stukalov_A549_72h_NSP15 | 4 | Interactome | A549 | NSP15 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 0 (0%) | 3 (75%) | |
COVID116 | Interactome_Stukalov_A549_72h_NSP16 | 2 | Interactome | A549 | NSP16 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 1 (50%) | 2 (100%) | |
COVID117 | Interactome_Stukalov_A549_72h_NSP2 | 1 | Interactome | A549 | NSP2 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 0 (0%) | 1 (100%) | |
COVID118 | Interactome_Stukalov_A549_72h_NSP3_MACROD | 2 | Interactome | A549 | NSP3_MACROD | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 0 (0%) | 1 (50%) | |
COVID119 | Interactome_Stukalov_A549_72h_NSP4 | 11 | Interactome | A549 | NSP4 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 9 (82%) | 9 (82%) | |
COVID120 | Interactome_Stukalov_A549_72h_NSP6 | 81 | Interactome | A549 | NSP6 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 44 (54%) | 46 (57%) | |
COVID121 | Interactome_Stukalov_A549_72h_NSP7 | 5 | Interactome | A549 | NSP7 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 5 (100%) | 3 (60%) | |
COVID122 | Interactome_Stukalov_A549_72h_NSP8 | 3 | Interactome | A549 | NSP8 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 2 (67%) | 2 (67%) | |
COVID123 | Interactome_Stukalov_A549_72h_NSP9 | 6 | Interactome | A549 | NSP9 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 4 (67%) | 4 (67%) | |
COVID124 | Interactome_Stukalov_A549_72h_ORF3 | 300 | Interactome | A549 | ORF3 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 199 (66%) | 190 (63%) | |
COVID125 | Interactome_Stukalov_A549_72h_ORF7A | 56 | Interactome | A549 | ORF7A | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 39 (70%) | 24 (43%) | |
COVID126 | Interactome_Stukalov_A549_72h_ORF7B | 300 | Interactome | A549 | ORF7B | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 203 (68%) | 173 (58%) | |
COVID127 | Interactome_Stukalov_A549_72h_ORF8 | 29 | Interactome | A549 | ORF8 | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 18 (62%) | 25 (86%) | |
COVID128 | Interactome_Stukalov_A549_72h_ORF9B | 2 | Interactome | A549 | ORF9B | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 1 (50%) | 2 (100%) | |
COVID129 | Interactome_Stukalov_A549_72h_S | 2 | Interactome | A549 | S | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 1 (50%) | 2 (100%) | |
COVID130 | Phosphoproteome_Stukalov_A549-ACE2_24h_Down | 300 | Phosphoproteome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 169 (56%) | 213 (71%) |
COVID131 | Phosphoproteome_Stukalov_A549-ACE2_24h_Up | 300 | Phosphoproteome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 190 (63%) | 229 (76%) |
COVID132 | Phosphoproteome_Stukalov_A549-ACE2_6h_Down | 70 | Phosphoproteome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 52 (74%) | 61 (87%) |
COVID133 | Phosphoproteome_Stukalov_A549-ACE2_6h_Up | 70 | Phosphoproteome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 44 (63%) | 58 (83%) |
COVID134 | Proteome_Stukalov_A549-ACE2_24h_Down | 300 | Proteome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 178 (59%) | 200 (67%) |
COVID135 | Proteome_Stukalov_A549-ACE2_24h_Up | 133 | Proteome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 92 (69%) | 103 (77%) |
COVID136 | Proteome_Stukalov_A549-ACE2_6h_Down | 10 | Proteome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 9 (90%) | 9 (90%) |
COVID137 | Proteome_Stukalov_A549-ACE2_6h_Up | 8 | Proteome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 8 (100%) | 5 (62%) |
COVID138 | Proteome_Stukalov_A549_72h_E_Down | 242 | Proteome | A549 | E | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 206 (85%) | 135 (56%) |
COVID139 | Proteome_Stukalov_A549_72h_E_Up | 190 | Proteome | A549 | E | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 144 (76%) | 112 (59%) |
COVID140 | Proteome_Stukalov_A549_72h_M_Down | 173 | Proteome | A549 | M | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 147 (85%) | 97 (56%) |
COVID141 | Proteome_Stukalov_A549_72h_M_Up | 103 | Proteome | A549 | M | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 82 (80%) | 69 (67%) |
COVID142 | Proteome_Stukalov_A549_72h_NSP10_Down | 32 | Proteome | A549 | NSP10 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 26 (81%) | 16 (50%) |
COVID143 | Proteome_Stukalov_A549_72h_NSP10_Up | 48 | Proteome | A549 | NSP10 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 38 (79%) | 32 (67%) |
COVID144 | Proteome_Stukalov_A549_72h_NSP12_Down | 211 | Proteome | A549 | NSP12 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 145 (69%) | 111 (53%) |
COVID145 | Proteome_Stukalov_A549_72h_NSP12_Up | 41 | Proteome | A549 | NSP12 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 32 (78%) | 16 (39%) |
COVID146 | Proteome_Stukalov_A549_72h_NSP13_Down | 96 | Proteome | A549 | NSP13 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 57 (59%) | 69 (72%) |
COVID147 | Proteome_Stukalov_A549_72h_NSP13_Up | 121 | Proteome | A549 | NSP13 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 95 (79%) | 73 (60%) |
COVID148 | Proteome_Stukalov_A549_72h_NSP14_Down | 38 | Proteome | A549 | NSP14 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 29 (76%) | 23 (61%) |
COVID149 | Proteome_Stukalov_A549_72h_NSP14_Up | 45 | Proteome | A549 | NSP14 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 32 (71%) | 29 (64%) |
COVID150 | Proteome_Stukalov_A549_72h_NSP15_Down | 34 | Proteome | A549 | NSP15 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 29 (85%) | 16 (47%) |
COVID151 | Proteome_Stukalov_A549_72h_NSP15_Up | 69 | Proteome | A549 | NSP15 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 56 (81%) | 39 (57%) |
COVID152 | Proteome_Stukalov_A549_72h_NSP16_Down | 39 | Proteome | A549 | NSP16 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 36 (92%) | 19 (49%) |
COVID153 | Proteome_Stukalov_A549_72h_NSP16_Up | 65 | Proteome | A549 | NSP16 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 54 (83%) | 38 (58%) |
COVID154 | Proteome_Stukalov_A549_72h_NSP1_Down | 213 | Proteome | A549 | NSP1 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 127 (60%) | 116 (54%) |
COVID155 | Proteome_Stukalov_A549_72h_NSP1_Up | 129 | Proteome | A549 | NSP1 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 83 (64%) | 70 (54%) |
COVID156 | Proteome_Stukalov_A549_72h_NSP2_Down | 121 | Proteome | A549 | NSP2 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 87 (72%) | 71 (59%) |
COVID157 | Proteome_Stukalov_A549_72h_NSP2_Up | 70 | Proteome | A549 | NSP2 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 47 (67%) | 37 (53%) |
COVID158 | Proteome_Stukalov_A549_72h_NSP3_MACROD_Down | 48 | Proteome | A549 | NSP3_MACROD | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 38 (79%) | 34 (71%) |
COVID159 | Proteome_Stukalov_A549_72h_NSP3_MACROD_Up | 79 | Proteome | A549 | NSP3_MACROD | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 53 (67%) | 55 (70%) |
COVID160 | Proteome_Stukalov_A549_72h_NSP4_Down | 42 | Proteome | A549 | NSP4 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 31 (74%) | 23 (55%) |
COVID161 | Proteome_Stukalov_A549_72h_NSP4_Up | 82 | Proteome | A549 | NSP4 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 56 (68%) | 43 (52%) |
COVID162 | Proteome_Stukalov_A549_72h_NSP6_Down | 68 | Proteome | A549 | NSP6 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 52 (76%) | 36 (53%) |
COVID163 | Proteome_Stukalov_A549_72h_NSP6_Up | 65 | Proteome | A549 | NSP6 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 44 (68%) | 36 (55%) |
COVID164 | Proteome_Stukalov_A549_72h_NSP7_Down | 34 | Proteome | A549 | NSP7 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 26 (76%) | 18 (53%) |
COVID165 | Proteome_Stukalov_A549_72h_NSP7_Up | 40 | Proteome | A549 | NSP7 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 25 (62%) | 26 (65%) |
COVID166 | Proteome_Stukalov_A549_72h_NSP8_Down | 61 | Proteome | A549 | NSP8 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 47 (77%) | 40 (66%) |
COVID167 | Proteome_Stukalov_A549_72h_NSP8_Up | 52 | Proteome | A549 | NSP8 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 40 (77%) | 27 (52%) |
COVID168 | Proteome_Stukalov_A549_72h_NSP9_Down | 42 | Proteome | A549 | NSP9 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 35 (83%) | 26 (62%) |
COVID169 | Proteome_Stukalov_A549_72h_NSP9_Up | 55 | Proteome | A549 | NSP9 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 47 (85%) | 31 (56%) |
COVID170 | Proteome_Stukalov_A549_72h_N_Down | 139 | Proteome | A549 | N | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 116 (83%) | 84 (60%) |
COVID171 | Proteome_Stukalov_A549_72h_N_Up | 102 | Proteome | A549 | N | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 82 (80%) | 62 (61%) |
COVID172 | Proteome_Stukalov_A549_72h_ORF3_Down | 300 | Proteome | A549 | ORF3 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 211 (70%) | 189 (63%) |
COVID173 | Proteome_Stukalov_A549_72h_ORF3_Up | 293 | Proteome | A549 | ORF3 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 205 (70%) | 203 (69%) |
COVID174 | Proteome_Stukalov_A549_72h_ORF6_Down | 79 | Proteome | A549 | ORF6 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 64 (81%) | 52 (66%) |
COVID175 | Proteome_Stukalov_A549_72h_ORF6_Up | 91 | Proteome | A549 | ORF6 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 62 (68%) | 48 (53%) |
COVID176 | Proteome_Stukalov_A549_72h_ORF7A_Down | 67 | Proteome | A549 | ORF7A | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 54 (81%) | 42 (63%) |
COVID177 | Proteome_Stukalov_A549_72h_ORF7A_Up | 74 | Proteome | A549 | ORF7A | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 56 (76%) | 38 (51%) |
COVID178 | Proteome_Stukalov_A549_72h_ORF7B_Down | 123 | Proteome | A549 | ORF7B | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 95 (77%) | 73 (59%) |
COVID179 | Proteome_Stukalov_A549_72h_ORF7B_Up | 130 | Proteome | A549 | ORF7B | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 95 (73%) | 71 (55%) |
COVID180 | Proteome_Stukalov_A549_72h_ORF8_Down | 63 | Proteome | A549 | ORF8 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 44 (70%) | 37 (59%) |
COVID181 | Proteome_Stukalov_A549_72h_ORF8_Up | 80 | Proteome | A549 | ORF8 | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 50 (62%) | 45 (56%) |
COVID182 | Proteome_Stukalov_A549_72h_ORF9B_Down | 219 | Proteome | A549 | ORF9B | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 116 (53%) | 115 (53%) |
COVID183 | Proteome_Stukalov_A549_72h_ORF9B_Up | 116 | Proteome | A549 | ORF9B | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 67 (58%) | 61 (53%) |
COVID184 | Proteome_Stukalov_A549_72h_S_Down | 48 | Proteome | A549 | S | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 36 (75%) | 25 (52%) |
COVID185 | Proteome_Stukalov_A549_72h_S_Up | 63 | Proteome | A549 | S | Control | 72h | Significance defined by Supp Table. Features sorted by pvalue. | 46 (73%) | 37 (59%) |
COVID186 | RNA_Stukalov_A549-ACE2_12h_Down | 19 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 12h | Significance defined by Supp Table. Features sorted by pvalue. | 18 (95%) | 13 (68%) |
COVID187 | RNA_Stukalov_A549-ACE2_12h_Up | 13 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 12h | Significance defined by Supp Table. Features sorted by pvalue. | 10 (77%) | 11 (85%) |
COVID188 | RNA_Stukalov_A549-ACE2_18h_Down | 33 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 18h | Significance defined by Supp Table. Features sorted by pvalue. | 27 (82%) | 14 (42%) |
COVID189 | RNA_Stukalov_A549-ACE2_18h_Up | 66 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 18h | Significance defined by Supp Table. Features sorted by pvalue. | 54 (82%) | 63 (95%) |
COVID190 | RNA_Stukalov_A549-ACE2_24h_Down | 39 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 26 (67%) | 26 (67%) |
COVID191 | RNA_Stukalov_A549-ACE2_24h_Up | 96 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 81 (84%) | 87 (91%) |
COVID192 | RNA_Stukalov_A549-ACE2_30h_Down | 102 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 30h | Significance defined by Supp Table. Features sorted by pvalue. | 47 (46%) | 58 (57%) |
COVID193 | RNA_Stukalov_A549-ACE2_30h_Up | 297 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 30h | Significance defined by Supp Table. Features sorted by pvalue. | 166 (56%) | 232 (78%) |
COVID194 | RNA_Stukalov_A549-ACE2_3h_Down | 2 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 3h | Significance defined by Supp Table. Features sorted by pvalue. | 2 (100%) | 1 (50%) |
COVID195 | RNA_Stukalov_A549-ACE2_3h_Up | 16 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 3h | Significance defined by Supp Table. Features sorted by pvalue. | 8 (50%) | 15 (94%) |
COVID196 | RNA_Stukalov_A549-ACE2_6h_Down | 16 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 15 (94%) | 10 (62%) |
COVID197 | RNA_Stukalov_A549-ACE2_6h_Up | 6 | RNA-seq | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 6 (100%) | 5 (83%) |
COVID198 | Ubiquitinome_Stukalov_A549-ACE2_24h_Down | 202 | Ubiquitinome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 148 (73%) | 142 (70%) |
COVID199 | Ubiquitinome_Stukalov_A549-ACE2_24h_Up | 300 | Ubiquitinome | A549-ACE2 | SARS-CoV-2 | Mock | 24h | Significance defined by Supp Table. Features sorted by pvalue. | 198 (66%) | 202 (67%) |
COVID200 | Ubiquitinome_Stukalov_A549-ACE2_6h_Down | 255 | Ubiquitinome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 170 (67%) | 173 (68%) |
COVID201 | Ubiquitinome_Stukalov_A549-ACE2_6h_Up | 103 | Ubiquitinome | A549-ACE2 | SARS-CoV-2 | Mock | 6h | Significance defined by Supp Table. Features sorted by pvalue. | 83 (81%) | 74 (72%) |
COVID ID | List Name | Size | Technology | Source | Treatment | Reference | TimePoints | Comments | #Found Multiple Times | #Found in Other Studies |
---|---|---|---|---|---|---|---|---|---|---|
  | Combined | 1375 | 786 (57%) | |||||||
COVID029 | RNA_Liao_BALF-mild_Down | 300 | RNA-seq | BALF | SARS-CoV-2 (mild) | uninfected | 123 (41%) | 165 (55%) | ||
COVID030 | RNA_Liao_BALF-mild_Up | 300 | RNA-seq | BALF | SARS-CoV-2 (mild) | uninfected | 106 (35%) | 132 (44%) | ||
COVID031 | RNA_Liao_BALF-severe_Down | 300 | RNA-seq | BALF | SARS-CoV-2 (severe) | uninfected | 233 (78%) | 145 (48%) | ||
COVID032 | RNA_Liao_BALF-severe_Up | 300 | RNA-seq | BALF | SARS-CoV-2 (severe) | uninfected | 156 (52%) | 248 (83%) | ||
COVID033 | RNA_Liao_BALF-severe-vs-mild_Down | 300 | RNA-seq | BALF | SARS-CoV-2 (severe) | SARS-CoV-2 (mild) | 141 (47%) | 118 (39%) | ||
COVID034 | RNA_Liao_BALF-severe-vs-mild_Up | 300 | RNA-seq | BALF | SARS-CoV-2 (severe) | SARS-CoV-2 (mild) | 74 (25%) | 226 (75%) |